2021
Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
Moura F, Itamar R, Cahn A, Goodrich E, Bhatt D, Leiter L, WILDING J, Gause-nilsson I, Mosenzon O, Sabatine M, Wiviott S. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation 2021, 144: a13182-a13182. DOI: 10.1161/circ.144.suppl_1.13182.Peer-Reviewed Original ResearchHDL-CMetabolic syndromeProgression to MetSAssociation of MetSClassification of MetSPrevalence of MetSHDL-C <Prediction of CV deathRandomized to dapagliflozinComponents of MetSPresence of MetSEffects of dapagliflozinLow HDL-CType 2 diabetes mellitusFollow-up visitAssociated with outcomeType 2 diabetesIDF criteriaBaseline characteristicsCV deathSGLT2 inhibitorsDapagliflozin armHeart failureSub-analysisElevated BP
2016
ST-elevation myocardial infarction risk in the very elderly
Campos A, Placido-Sposito A, Freitas W, Moura F, Guariento M, Nadruz W, Moriguchi E, Sposito A, Study O. ST-elevation myocardial infarction risk in the very elderly. BBA Clinical 2016, 6: 108-112. PMID: 27635386, PMCID: PMC5024138, DOI: 10.1016/j.bbacli.2016.09.001.Peer-Reviewed Original ResearchModerate to severe depressive symptomsST-segment elevation myocardial infarctionSevere depressive symptomsDepressive symptomsGlomerular filtration rateAttributable riskMortality of ST-segment elevation myocardial infarctionOdds ratioReduced levels of HDL-CHDL-CMild depressive symptomsMyocardial infarction riskMale genderLow HDL-CHigh LDL-CCase-control studyReduced HDL-CST-segment elevation myocardial infarction patientsMultivariate regression modelLow glomerular filtration rateAssociated with ST-segment elevation myocardial infarctionLevels of HDL-CInfarction riskElevation myocardial infarctionSmoking habits
2014
Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial
Figueiredo V, Vendrame F, Colontoni B, Quinaglia T, Matos-Souza J, Moura F, Coelho O, de Faria E, Sposito A. Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. Clinical Therapeutics 2014, 36: 961-966. PMID: 24768191, DOI: 10.1016/j.clinthera.2014.03.012.Peer-Reviewed Original ResearchConceptsEffects of extended-release niacinFlow-mediated dilationExtended-release niacinHDL-C levelsHDL-CEndothelial functionDay 7Reduced plasma concentrations of high-density lipoprotein cholesterolLow HDL-C levelsHDL-C levels <Plasma concentrations of high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolConcentrations of high-density lipoprotein cholesterolLow HDL-C.Low HDL-CHeme oxygenase-1 pathwayTreatment period 1C-reactive proteinPlasma HDL-CTreatment period 2Improving endothelial functionEffects of niacinTransfer protein activityShort-term effectsReduced plasma concentrations